Phenylephrine/ketorolac, sold under the brand name Omidria, is a combination drug used during cataract surgery[3] or intraocular lens replacement to prevent intraoperative miosis and to reduce postoperative pain.[1] It contains phenylephrine and ketorolac.[1]
| Combination of | |
|---|---|
| Phenylephrine | Alpha-1 adrenergic receptor agonist |
| Ketorolac | Nonsteroidal anti-inflammatory |
| Clinical data | |
| Trade names | Omidria |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Intraocular |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Phenylephrine/ketorolac was approved for medical use in the United States in May 2014,[4] and in the European Union in July 2015.[2]
References
edit- ^ a b c "Omidria- phenylephrine and ketorolac injection, solution, concentrate". DailyMed. 11 December 2017. Retrieved 17 April 2020.
- ^ a b "Omidria EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 17 April 2020.
- ^ Lawuyi LE, Gurbaxani A (2015). "The clinical utility of new combination phenylephrine/ketorolac injection in cataract surgery". Clinical Ophthalmology. 9. Auckland, N.Z.: 1249–54. doi:10.2147/OPTH.S72321. PMC 4506037. PMID 26203214.
- ^ "Drug Approval Package: Omidria (phenylephrine and ketorolac) Injection NDA #205388". U.S. Food and Drug Administration (FDA). 9 December 2014. Retrieved 17 April 2020.
External links
edit- "Ketorolac mixture with phenylephrine". Drug Information Portal. U.S. National Library of Medicine.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |